10.3390/curroncol30070454 - Capecitabine Plus Aromatase Inhibitor...

This document has been corrected

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

10.3390/curroncol30070454

Published Online: 2023-06-24

Journal: Current Oncology•Publisher: MDPI AG

Authors: Alberto Alvarado-Miranda•Alberto Guijosa•Claudia Haydee Arce Salinas•Cynthia Villarreal Garza•Daniel Sanchez Benitez•Fernando Ulises Lara-Medina•Jesús Alberto Limón Rodríguez•Juan W. Zinser-Sierra•Oscar Arrieta•Paula Anel Cabrera Galeana•Wendy R. Muñoz-Montaño

This document has been corrected

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

10.3390/curroncol30070454

Published Online: 2023-06-24

Journal: Current Oncology

NOW

2023-06-24•Correction

Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097–6110

10.3390/curroncol31110529

* information provided by CrossRef

2023-06-24•Correction

10.3390/curroncol31110529

* information provided by CrossRef

2023-06-24•Published

2023-06-24•Correction

10.3390/curroncol31110529

* information provided by CrossRef

This document has been corrected

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

10.3390/curroncol30070454

Published Online: 2023-06-24

Journal: Current Oncology•Publisher: MDPI AG